Guerzoni, Simona
Castro, Flavia Lo https://orcid.org/0000-0002-8572-3421
Brovia, Daria
Baraldi, Carlo
Pani, Luca
Article History
Received: 29 August 2023
Accepted: 25 October 2023
First Online: 6 November 2023
Declarations
:
: Data were desumed from patients enrolled in two studies approved by the AVEN Ethics Committee (protocol numbers: 625/2020/OSS/AOUMO and 50/2020/OSS/AOUMO). The study was conducted according to the latest version of the Declaration of Helsinki.
: All patients signed a free-informed consent for study participation and data publication.
: SG received fees and honoraria from Teva, Eli Lilly, Allergan/Abbvie, Novartis, Pfizer, and Lundbeck; CB received fees and honoraria from Teva, Eli Lilly, Allergan/Abbvie, Novartis, and Lundbeck. LP has been a scientific consultant for AbbVie, USA; Acadia, USA; BCG, Switzerland; Boehringer Ingelheim International GmbH, Germany; Compass Pathways, UK; Immunogen, USA; Inpeco SA, Switzerland; Johnson & Johnson USA; Novartis-Gene Therapies, Switzerland; Sanofi-Aventis-Genzyme, France and USA; Nurosene-NetraMark, Canada; Pfizer Global, USA; PharmaMar, Spain; Relmada Therapeutics, USA; Takeda, USA; Vifor, Switzerland; and WCG-VeraSci/Clinical Endpoint Solutions, USA, and he owns shares of Relmada, USA, and NetraMark, Canada. FLC and BD have no conflict of interest to disclose.